Evidence map›Paper›PMID 29250574›Full record

ArticleBio-protocol2017

RNA Interference Screening to Identify Proliferation Determinants in Breast Cancer Cells.

Yong-Wei Zhang, Rochelle E Nasto, Sandra A Jablonski, Ilya G Serebriiskii, Rishi Surana, Joseph Murray, Michael Johnson, Rebecca B Riggins, Robert Clarke, Erica A Golemis and 1 more

Abstract read
In one paragraph

Article in Bio-protocol, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yong-Wei ZhangLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Rochelle E NastoLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Sandra A JablonskiLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Ilya G SerebriiskiiProgram in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA, USA.
Rishi SuranaLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Joseph MurrayLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Michael JohnsonLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Rebecca B RigginsLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Robert ClarkeLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Erica A GolemisProgram in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA, USA.
Louis M WeinerLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI STEPHEN W BYERS · 1990 to 2026
$71.5M
Novel Targets in Endocrine ResponsivenessU54CA149147 · NCI · GEORGETOWN UNIVERSITY · PI CLARKE, ROBERT R. · 2010 to 2014
$6.9M
TARGETED IMMUNOTHERAPY USING BISPECIFIC ANTIBODIESR01CA050633 · NCI · GEORGETOWN UNIVERSITY · PI WEINER, LOUIS M. · 1989 to 2018
$6.5M
ROLES OF HEF1 IN CELL DIFFERENTIATION AND SURVIVALR01CA063366 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI GOLEMIS, ERICA A. · 1998 to 2013
$3.9M
A Role for AMH Autocrine Signaling in NSCLCR21CA181287 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI GOLEMIS, ERICA A. · 2014 to 2015
$421k
NCI NIH HHS P30 CA051008NCI NIH HHS R01 CA050633NCI NIH HHS R01 CA063366NCI NIH HHS R21 CA181287NCI NIH HHS U54 CA149147
6 · The paper itself

Abstract

RNAi screening technology has revealed unknown determinants of various biological signaling pathways in biomedical studies. This protocol provided detailed information about how to use RNAi screening to identify proliferation determinants in breast tumor cells. siRNA-based libraries targeting against Estrogen receptor (ER)-network, including 631 genes relevant to estrogen signaling, was constructed for screening in breast cancer cells. Briefly, reverse transfection of siRNA induced transient gene knockdown in MCF7 cells. First, the transfection reagent for MCF7 cells was selected. Next, the Z'-score assay was used to monitor if screening conditions yielded efficiently. Then, the ER-network siRNA library screening was preceded by automatic machines under optimized experimental conditions.

Indexed as

Breast cancerCyBio automatic dispenserEstrogen receptor (ER)Multidrop Combi-nL reagent dispenserRNA interference (RNAi)ScreeningWellMate microplate dispenserZ′-score

Identifiers

PMID29250574
PMCPMC5730085

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.